Newsbenzinga
Rocket Pharmaceuticals Touts Positive Early Safety Data from Revised Genetic Therapy Trial
· Published
Article summary
Rocket Pharmaceuticals announces positive early safety results for its RP-A501 Phase 2 trial in Danon disease and plans further FDA talks.
An excerpt from the original article.
Comments —
Loading comments…